Skip to main content
Premium Trial:

Request an Annual Quote

Short Reads: Oct 1, 2003

Premium

The new director of the National Institute of General Medical Sciences is Jeremy Berg, who comes from Johns Hopkins University School of Medicine. Berg, who is expected to take over next month, replaces Judith Greenberg.

 

Due to its merger with Personal Chemistry, Pyrosequencing has a new team in charge: Hans Johansson is president and COO; Jon-Sverre Schanche is vice president of R&D; and Scott Carr becomes president of the merged US subsidiary firms. Those who continue their posts are Jeff Bork, still CEO; Mats-Olof Wallin, CFO; and Marten Winge, marketing VP. Erik Wallden, meanwhile, steps down from his role as president of Pyrosequencing.

 

Catherine Burzik, former president of Ortho-Clinical Diagnostics, a Johnson & Johnson company, heads to Applied Biosystems as executive vice president. Meanwhile, Patricia Scheller, who managed various business units at Ortho-Clinical, is named the CEO of SomaLogic, a proteomics company.

 

Robert Stein resigns from Incyte, where he was president and CSO. Stein leaves to take a position at an undisclosed West Coast life sciences firm. In other news, Celgene’s Richard Levy leaves to become senior vice president of drug development at Incyte.

Invitrogen names Claude Benchimol to the newly created position of senior vice president of R&D. Benchimol comes from General Electric, where he led the company’s medical systems and IT division in developing a technology pipeline.

 

Ira Marks, most recently at Nanogen as the senior vice president for corporate development and international operations, takes the helm as vice president for worldwide sales and marketing at Cepheid.

 

Jim Golden, who in early 2002 became business development manager for CuraGen’s 454 subsidiary, leaves to be a senior VP and research director at a new Boston-based drug discovery technology analyst firm spinning out of Cambridge Healthtech Institute.

 

Robert Johnson is the new president and COO of Spectral Genomics, a Houston-based microarray manufacturer and provider. Prior to this, Johnson spent 18 years at Baxter Healthcare and five years at VitaGen. Meantime, Ed Chait comes from PharmaCore to be the new CEO of Spectral Genomics.

 

Quark Biotech announces the arrival of John Delyani as vice president of business development. Delyani comes to Quark from Pharmacia, where he was director of technology acquisition and operations.

 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.